Which place for avelumab in the management of urothelial carcinoma?-Reference-Cited by-同舟云学术

Which place for avelumab in the management of urothelial carcinoma?

Published:2019-07-09 Issue:9 Volume:19 Page:863-870
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Larroquette Mathieu¹,Gross-Goupil Marine¹,Daste Amaury¹,Robert Grégoire²,Ravaud Alain¹²³,Domblides Charlotte¹²³

Affiliation:

1. Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France

2. Department of Urology, Bordeaux University Hospital, Bordeaux, France

3. Bordeaux University, Bordeaux, France

Funder

not funded

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1637412

Reference45 articles.

1. Bladder cancer

2. European cancer information system [Internet]. [cited 2019 Feb 27]. Available from: https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1,2$3-38$6-0,14$5-2008,2008$7-7$CEstByCountry$X0_8-3$X0_19-AE28E$X0_20-No$CEstRelative$X1_8-3$X1_9-AE28$X1_19-AE28E$CEstByCountryTable$X2_19-AE28E

3. Association Between Smoking and Risk of Bladder Cancer Among Men and Women

4. Professionals S-O Non-muscle-invasive Bladder Cancer [Internet]. Uroweb. [cited 2019 Feb 13]. Available from: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/

5. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The detection of PD‐L1 expression on liquid‐based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid‐based cytology and cell block samples;Diagnostic Cytopathology;2024-01-23

2. Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life;European Journal of Pharmaceutical Sciences;2021-10

3. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners;Cancer and Metastasis Reviews;2021-07-08

4. Immune checkpoint: The novel target for antitumor therapy;Genes & Diseases;2021-01